Aaron S. Mansfield, M.D., is a translational scientist with a focus on early-phase clinical trials, especially for lung cancer and mesothelioma. Dr. Mansfield's research is focused on understanding how tumors avoid destruction by the immune system.
- Tumor immunology. Dr. Mansfield characterizes the heterogeneity of programmed cell death ligand 1 in lung cancer and its effects on immune responses. He is also investigating the use of blood-based biomarkers to predict responses to immunotherapies.
- Early drug development. Dr. Mansfield is the principal investigator of the ROS1-crizotinib arm of the National Cancer Institute-sponsored Molecular Analysis for Therapy Choice (NCI-MATCH) clinical trial. He has also characterized the effect of hepatic impairment on outcomes in phase I clinical trials and is part of ongoing efforts to design clinical trials of novel combinations for mesothelioma.
- Thrombosis in cancer. Dr. Mansfield has characterized the patterns of thrombotic events and their prognostic significance in lung cancer. He continues to work on the discovery of biomarkers and the development of models that will help select patients for prophylaxis against cancer-associated thrombosis.
Significance to patient care
Dr. Mansfield hopes to introduce novel treatments and tools to treat lung cancer, mesothelioma and their associated complications.
- Principal investigator, ROS1-crizotinib arm of the NCI-MATCH, National Cancer Institute, 2015-present
- Recipient, American Society of Clinical Oncology (ASCO) travel award, 2013
- Recipient, Tow Shung Tan Humanism in Medicine Award, 2013
- Recipient, ASCO Merit Awards, 2012